Revive Therapeutics Ltd. focuses on developing therapeutics and diagnostics for infectious diseases and rare disorders. The company faces significant concerns, including a staggering ROA of -5370.8% and a very low current ratio of 0.02, indicating severe liquidity issues. Additionally, the stock price has dropped 20% today, reflecting market skepticism. While the company's focus on niche therapeutic areas could offer potential upside, its financial health raises red flags for investors.
Loading financial metrics...
Company has $15K in cash but burned $192K last quarter. At this burn rate, only 0.1 quarters of runway remain without additional financing.
Company posted a loss of $-11.0M over the last year, representing Infinity% of revenue.
Debt of $67K is 4.6x the company's cash position of $15K.
Operating cash flow has been negative for 3 consecutive quarters, burning $768K over the last year.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2025-FY (June 30, 2025)